2013
DOI: 10.4314/ijbcs.v6i6.36
|View full text |Cite
|
Sign up to set email alerts
|

Problématique du contrôle et de la prévention de la coccidiose du poulet

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 44 publications
0
3
0
Order By: Relevance
“…Therefore, coccidiosis severity is positively correlated with the charge of ingested oocysts. The pathogenicity of coccidia depends on the species involved, the number of oocysts ingested and the host’s immune competence (Dakpogan et al 2012).…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, coccidiosis severity is positively correlated with the charge of ingested oocysts. The pathogenicity of coccidia depends on the species involved, the number of oocysts ingested and the host’s immune competence (Dakpogan et al 2012).…”
Section: Discussionmentioning
confidence: 99%
“…The high prevalence of infestations could be explained by non-compliance with prophylaxis plans on poultry farms, i.e. inappropriate management of litter and sanitary emptying, as coccidian oocysts sporulate very easily in poultry house litter(Dakpogan et al 2012). Moreover, our prevalence is higher than that reported by other studies: 54.3% in Turkey(Karaer et al, 2012), 31.7% and 39.6% in India(Sharma et al, 2013), 36.7% and 52.9% in Nigeria(Muazu et al, 2008) in poultry production in general.…”
mentioning
confidence: 99%
“…Monensin selectively destroys intracellular sporozoites while remaining relatively noninjurious to the host cell (Chapman et al, 2010). Monensin is primarily coccidiocidal in action and active against Eimeria acervulina, E. maxima, E. brunetti, E. mivati, E. necatrix and E. tenella in chickens (Dakpogan et al, 2013). In Europe, two feed additives, Ealncoban (Elanco, St Cloud, France) and Coxidin (Huvepharma, NV, Belgium), containing monensin have obtained market authorization.…”
mentioning
confidence: 99%